{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:40:11Z","timestamp":1786977611579,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":3921,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5\u2009mg bid compared with placebo (with standard care) after an exacerbation of HF in patients with reduced ejection fraction (HF-rEF) and documented coronary artery disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is an international prospective, multicentre, randomized, double-blind, placebo-controlled, event-driven study of approximately 5000 patients for a targeted 984 events. Patients must have a recent symptomatic exacerbation of HF, increased plasma concentrations of natriuretic peptides (B-type natriuretic peptide \u2265200\u2009pg\/mL or N-terminal pro\u2013B-type natriuretic peptide \u2265800\u2009pg\/mL), with left ventricular ejection fraction \u226440% and coronary artery disease. Patients requiring anticoagulation for atrial fibrillation or other conditions will be excluded. After an index event (overnight hospitalization, emergency department or observation unit admission, or unscheduled outpatient parenteral treatment for worsening HF), patients will be randomized 1:1 to rivaroxaban or placebo (with standard of care). The primary efficacy outcome event is a composite of all-cause mortality, myocardial infarction or stroke. The principal safety outcome events are the composite of fatal bleeding or bleeding into a critical space with potential permanent disability, bleeding events requiring hospitalization and major bleeding events according to International Society on Thrombosis and Haemostasis bleeding criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>COMMANDER HF is the first prospective study of a target-specific oral antithrombotic agent in HF. It will provide important information regarding rivaroxaban use following an HF event in an HF-rEF patient population with coronary artery disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.266","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T06:03:33Z","timestamp":1430114613000},"page":"735-742","source":"Crossref","is-referenced-by-count":70,"title":["Rationale and Design of a Randomized, Double-Blind, Event-Driven, Multicentre Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Exacerbation of Heart Failure: The COMMANDER HF Trial"],"prefix":"10.1093","volume":"17","author":[{"given":"Faiez","family":"Zannad","sequence":"first","affiliation":[{"name":"Inserm Centre d\u2019Investigation Clinique CIC 1433, UMR 1116, CHU de Nancy, Institut Lorrain du Coeur et des Vaisseaux , Universit\u00e9 de Lorraine, Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiology Division, University of California , San Diego, La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College , London ,","place":["England"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep R.","family":"Mehra","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital Heart and Vascular Center, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Division of Innovative Clinical Trials, Department of Cardiology, University Medical Centre G\u00f6ttingen (UMG) , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Byra","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , 920 US 202, Raritan, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fu","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , 920 US 202, Raritan, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Mills","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , 920 US 202, Raritan, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,4,27]]},"reference":[{"key":"2026011921092634700_ejhf266-bib-0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2026011921092634700_ejhf266-bib-0002","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.jacc.2014.07.978","article-title":"The heterogeneity of heart failure: will enhanced phenotyping be necessary for future clinical trial success?","volume":"64","author":"Francis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026011921092634700_ejhf266-bib-0003","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026011921092634700_ejhf266-bib-0004","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011921092634700_ejhf266-bib-0005","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1503\/cmaj.051620","article-title":"Management of acute decompensated heart failure","volume":"176","author":"Allen","year":"2007","journal-title":"CMAJ"},{"key":"2026011921092634700_ejhf266-bib-0006","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.jacc.2007.02.037","article-title":"Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure","volume":"49","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026011921092634700_ejhf266-bib-0007","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction","volume":"61","author":"van Veldhuisen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011921092634700_ejhf266-bib-0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2013.07.007","article-title":"Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives","volume":"2","author":"Gurbel","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026011921092634700_ejhf266-bib-0009","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10741-012-9343-x","article-title":"Anticoagulation in heart failure: current status and future direction","volume":"18","author":"Gheorghiade","year":"2013","journal-title":"Heart Fail Rev"},{"key":"2026011921092634700_ejhf266-bib-0010","article-title":"Anticoagulation versus placebo for heart failure in sinus rhythm","volume":"3","author":"Lip","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026011921092634700_ejhf266-bib-0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The Warfarin\/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"key":"2026011921092634700_ejhf266-bib-0012","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1388-9842(99)00055-0","article-title":"Antithrombotic therapy in heart failure: a randomized comparison of warfarin vs. aspirin (HELAS)","volume":"1","author":"Cokkinos","year":"1999","journal-title":"Eur J Heart Fail"},{"key":"2026011921092634700_ejhf266-bib-0013","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"key":"2026011921092634700_ejhf266-bib-0014","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ijcard.2012.12.018","article-title":"Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges","volume":"167","author":"Zannad","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026011921092634700_ejhf266-bib-0015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/CIRCULATIONAHA.111.044149","article-title":"Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials","volume":"125","author":"Masson","year":"2012","journal-title":"Circulation"},{"key":"2026011921092634700_ejhf266-bib-0016","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cca.2014.08.016","article-title":"Troponins in heart failure","volume":"443","author":"Omland","year":"2014","journal-title":"Clin Chem Acta"},{"key":"2026011921092634700_ejhf266-bib-0017","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ahj.2012.03.004","article-title":"Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure","volume":"163","author":"de Antonio","year":"2012","journal-title":"Am Heart J"},{"key":"2026011921092634700_ejhf266-bib-0018","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.amjcard.2012.04.033","article-title":"Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure","volume":"110","author":"Egstrup","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026011921092634700_ejhf266-bib-0019","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/cvr\/cvp066","article-title":"Is thrombin a key player in the \u2018coagulation-atherogenesis\u2019 maze?","volume":"82","author":"Borissoff","year":"2009","journal-title":"Cardiovasc Res"},{"key":"2026011921092634700_ejhf266-bib-0020","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00109-013-1074-5","article-title":"Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond","volume":"91","author":"Danckwardt","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"2026011921092634700_ejhf266-bib-0021","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/eurjhf\/hft135","article-title":"New oral anticoagulants in heart failure","volume":"15","author":"Van Gelder","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011921092634700_ejhf266-bib-0022","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/eurjhf\/hft031","article-title":"CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials","volume":"15","author":"Ueland","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011921092634700_ejhf266-bib-0023","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.109.928846","article-title":"Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial","volume":"122","author":"Anand","year":"2010","journal-title":"Circulation"},{"key":"2026011921092634700_ejhf266-bib-0024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacc.2008.08.074","article-title":"Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease","volume":"53","author":"Kitta","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026011921092634700_ejhf266-bib-0025","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/01.CIR.0000153349.77489.CF","article-title":"Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure","volume":"111","author":"Katz","year":"2005","journal-title":"Circulation"},{"key":"2026011921092634700_ejhf266-bib-0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijcard.2011.01.059","article-title":"Predictive value of serial assessment of endothelial function in chronic heart failure","volume":"158","author":"Takishima","year":"2012","journal-title":"Int J Cardiol"},{"key":"2026011921092634700_ejhf266-bib-0027","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2141.2004.04977.x","article-title":"Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation","volume":"126","author":"Cugno","year":"2004","journal-title":"Br J Haematol"},{"key":"2026011921092634700_ejhf266-bib-0028","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1538-7836.2006.01916.x","article-title":"Markers of hypercoagulability and inflammation predict mortality in patients with heart failure","volume":"4","author":"Marcucci","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2026011921092634700_ejhf266-bib-0029","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11239-011-0635-0","article-title":"Increased d-dimer levels predict cardiovascular mortality in patients with systolic heart failure","volume":"33","author":"Zorlu","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"2026011921092634700_ejhf266-bib-0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.ATV.0000046238.23903.FC","article-title":"The dynamics of thrombin formation","volume":"23","author":"Mann","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026011921092634700_ejhf266-bib-0031","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1177\/0091270007302952","article-title":"Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity","volume":"47","author":"Graff","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"2026011921092634700_ejhf266-bib-0032","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2141.2010.08433.x","article-title":"The impact of elective knee\/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation","volume":"151","author":"Green","year":"2010","journal-title":"Br J Haematol"},{"key":"2026011921092634700_ejhf266-bib-0033","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.healun.2010.08.027","article-title":"Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure","volume":"30","author":"Gheorghiade","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"2026011921092634700_ejhf266-bib-0034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2026011921092634700_ejhf266-bib-0035","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026011921092634700_ejhf266-bib-0036","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2010.04.092","article-title":"Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure","volume":"151","author":"Gheorghiade","year":"2011","journal-title":"Int J Cardiol"},{"key":"2026011921092634700_ejhf266-bib-0037","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.acvd.2011.10.007","article-title":"The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use","volume":"105","author":"Januzzi","year":"2012","journal-title":"Arch Cardiovasc Dis"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.266","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.266","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/7\/735\/66422522\/eurjhf_17_7_735.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/7\/735\/66422522\/eurjhf_17_7_735.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:09:48Z","timestamp":1768874988000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/17\/7\/735\/8426486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,27]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,4,27]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.266","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,7]]},"published":{"date-parts":[[2015,4,27]]}}}